Raven Industries, Inc. (RAVN) Is At $36.15 Formed Wedge; Alliqua Biomedical (ALQA) Sellers Decreased By 8.83% Their Shorts

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Logo

Alliqua Biomedical Inc (NASDAQ:ALQA) had a decrease of 8.83% in short interest. ALQA’s SI was 196,200 shares in April as released by FINRA. Its down 8.83% from 215,200 shares previously. With 30,100 avg volume, 7 days are for Alliqua Biomedical Inc (NASDAQ:ALQA)’s short sellers to cover ALQA’s short positions. The SI to Alliqua Biomedical Inc’s float is 5.98%. The stock increased 0.87% or $0.02 during the last trading session, reaching $2.31. About 30,564 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 69.15% since April 17, 2017 and is downtrending. It has underperformed by 80.70% the S&P500.

Raven Industries, Inc. (RAVN) formed wedge up with $37.23 target or 3.00% above today’s $36.15 share price. Raven Industries, Inc. (RAVN) has $1.30 billion valuation. The stock increased 2.26% or $0.8 during the last trading session, reaching $36.15. About 58,218 shares traded. Raven Industries, Inc. (NASDAQ:RAVN) has risen 18.49% since April 17, 2017 and is uptrending. It has outperformed by 6.94% the S&P500.

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. The rating was downgraded by H.C. Wainwright to “Neutral” on Monday, January 8. The company was maintained on Friday, November 6 by Chardan Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Friday, November 6. The stock has “Buy” rating by H.C. Wainwright on Monday, November 2. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) has “Buy” rating given on Friday, April 7 by H.C. Wainwright. The firm has “Outperform” rating given on Wednesday, February 24 by RBC Capital Markets. H.C. Wainwright maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) on Wednesday, August 10 with “Buy” rating. H.C. Wainwright maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) on Wednesday, January 3 with “Buy” rating. On Wednesday, February 24 the stock rating was maintained by Chardan Capital Markets with “Buy”. The firm earned “Hold” rating on Wednesday, August 19 by Zacks.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $11.56 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Among 4 analysts covering Raven Industries (NASDAQ:RAVN), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Raven Industries has $41.0 highest and $31.0 lowest target. $35.33’s average target is -2.27% below currents $36.15 stock price. Raven Industries had 12 analyst reports since March 11, 2016 according to SRatingsIntel. On Friday, March 11 the stock rating was downgraded by Dougherty & Company to “Neutral”. The stock has “Neutral” rating by Dougherty on Tuesday, December 5. Piper Jaffray maintained it with “Hold” rating and $3300 target in Thursday, July 27 report. On Friday, November 3 the stock rating was maintained by Piper Jaffray with “Hold”. The firm has “Buy” rating given on Friday, February 17 by Dougherty & Company. The firm has “Neutral” rating given on Thursday, December 15 by Piper Jaffray. On Thursday, August 24 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was maintained by Piper Jaffray on Tuesday, November 21 with “Hold”. Piper Jaffray maintained Raven Industries, Inc. (NASDAQ:RAVN) on Friday, September 29 with “Hold” rating. On Friday, October 6 the stock rating was maintained by SunTrust with “Hold”.

Analysts await Raven Industries, Inc. (NASDAQ:RAVN) to report earnings on May, 28. They expect $0.50 EPS, up 47.06% or $0.16 from last year’s $0.34 per share. RAVN’s profit will be $17.97 million for 18.08 P/E if the $0.50 EPS becomes a reality. After $0.24 actual EPS reported by Raven Industries, Inc. for the previous quarter, Wall Street now forecasts 108.33% EPS growth.

Raven Industries, Inc. (NASDAQ:RAVN) Institutional Positions Chart